Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

BusinessWire_EN 
0 0 10.11.20
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference: https://mms.businesswire.com/media/20200817005658/en/810396/5/deciphera-logo-color-RGB-TM_.jpg
 

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17 at 9:40 AM ET.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line GIST. QINLOCK is also approved in Canada and Australia for fourth-line GIST. For more information, visit www.Deciphera.com and follow us on Twitter (@Deciphera) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005273/en/

Deciphera Pharmaceuticals Stock

€23.40
0.860%
The Deciphera Pharmaceuticals stock is trending slightly upwards today, with an increase of €0.20 (0.860%) compared to yesterday's price.
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Deciphera Pharmaceuticals.
As a result the target price of 24 € shows a slightly positive potential of 2.56% compared to the current price of 23.4 € for Deciphera Pharmaceuticals.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!